136 related articles for article (PubMed ID: 34528573)
1. A case of trastuzumab-induced dermatomyositis.
Trontzas IP; Syrigos NK; Kotteas EA
J Cancer Res Ther; 2021; 17(4):1112-1114. PubMed ID: 34528573
[TBL] [Abstract][Full Text] [Related]
2. Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report.
Moghimi M; Khodadadi K
Case Rep Oncol; 2021; 14(2):1134-1138. PubMed ID: 34413744
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab-Associated Dermatomyositis.
Waheed S; Zubair HM; Waheed F; Iqbal SM
Am J Ther; 2019; 26(5):e647-e649. PubMed ID: 30239341
[No Abstract] [Full Text] [Related]
4. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
5. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
[TBL] [Abstract][Full Text] [Related]
6. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
[TBL] [Abstract][Full Text] [Related]
7. T1 invasive breast lobular tumor and ductal carcinoma with HER-2 positive characteristics: Is it rationale to use adjuvant trastuzumab?
Altundag K
J BUON; 2017; 22(4):1083. PubMed ID: 28952233
[No Abstract] [Full Text] [Related]
8. [Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer].
Guo J; Xu B; Ma F; Fan Y; Yuan P; Wang J; Cai R; Li Q; Zhang P
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):372-6. PubMed ID: 25030594
[TBL] [Abstract][Full Text] [Related]
9. [The requirements to clinicopathology about targeted therapy for breast cancer].
Jiang ZF; Shen G
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
[No Abstract] [Full Text] [Related]
10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
11. Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.
Baretta Z; Guindalini RS; Khramtsova G; Olopade OI
Clin Breast Cancer; 2013 Apr; 13(2):156-8. PubMed ID: 23276464
[No Abstract] [Full Text] [Related]
12. Interstitial pneumonitis associated with trastuzumab emtansine.
Alkan A
J Oncol Pharm Pract; 2019 Oct; 25(7):1798-1800. PubMed ID: 30426834
[TBL] [Abstract][Full Text] [Related]
13. Corneal Changes in Trastuzumab Emtansine Treatment.
Kreps EO; Derveaux T; Denys H
Clin Breast Cancer; 2018 Aug; 18(4):e427-e429. PubMed ID: 29615304
[No Abstract] [Full Text] [Related]
14. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
[TBL] [Abstract][Full Text] [Related]
16. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Falchook GS; Moulder SL; Wheler JJ; Jiang Y; Bastida CC; Kurzrock R
Ann Oncol; 2013 Dec; 24(12):3004-11. PubMed ID: 24158411
[TBL] [Abstract][Full Text] [Related]
17. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
18. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
